<DOC>
	<DOCNO>NCT00478777</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm phase 3B study combination lenalidomide plus pulse high-dose dexamethasone . This study ( CC-5013-MM-019 ) set execute primarily expanded access program Germany . Screening procedure take place within 28 day prior Cycle 1 Day 1 ( baseline ) exception hematology assessment perform within 14 day prior Cycle 1 Day 1 . Randomization , blinding , stratification apply open-label single-arm study . Eligible subject give open-label treatment receive treatment lenalidomide plus high-dose dexamethasone 28-day cycle . Lenalidomide ( hard capsule ) administer orally ( PO ) dose 25 mg daily ( QD ) first 21 day 28-day cycle . According protocol , accrual subject study terminate within 2 month commercial availability lenalidomide indication Germany . Upon discontinuation study , minimal information collect order identify disease progress .</brief_summary>
	<brief_title>A Multicenter , Single-Arm , Open-Label Expanded Access Program Lenalidomide Plus Dexamethasone Previously Treated Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form . Must ≥18 year age time sign informed consent form . Must able adhere study visit schedule protocol requirement . Must diagnose multiple myeloma progress least 2 cycle antimyeloma treatment relapse progressive disease treatment . Subjects may previously treat thalidomide and/or radiation therapy . In addition , radiation therapy initiate prior baseline ( Day 1 ) may give concurrently study therapy , provide eligibility criterion satisfy . Subjects must discontinue antimyeloma drug nondrug therapy prior first dose study drug exception radiation therapy initiate prior baseline ( Day 1 ) . Measurable level myeloma paraprotein serum ( &gt; 0.5 g/dL ) urine ( &gt; 0.2 g excrete 24hour collection sample ) . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start study drug ; 2 ) participate study ; 3 ) least 28 day discontinuation study . The presence follow exclude subject study enrollment : Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant lactating female . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm^3 ( 1.0 x 10^9/L ) Platelet count &lt; 75,000/mm^3 ( 75 x 109/L ) subject &lt; 50 % bone marrow nucleate cell plasma cell . Platelet count &lt; 30,000/mm^3 ( 30x10^9/L ) subject ≥50 % bone marrow nucleate cell plasma cell . Serum creatinine &gt; 2.5 mg/dL ( 221 µmol/L ) Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) Prior history malignancy multiple myeloma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥1 year . Prior history stroke and/or thromboembolic event Known hypersensitivity thalidomide dexamethasone . Prior history uncontrollable side effect dexamethasone therapy . The development desquamate rash take thalidomide . Neuropathy ≥ Grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Celgene</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>